RISA Extension Study - Long Term Safety
Recruitment status was Active, not recruiting
The primary purpose of this study is to gather additional safety data for the subjects treated with the Alair System (hereinafter, "Alair-Treated Subjects") who previously completed the one-year study entitled: "Multicenter Randomized Clinical Trial of Bronchial Thermoplasty with the Alair System for the Treatment of Severe Asthma" (Protocol #0903-27) sponsored by Asthmatx, Inc. Subjects who elect to participate in this safety study will be followed for an additional four (4) year period beyond the PREDECESSOR STUDY'S one-year endpoint.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Long Term Safety Evaluation of Bronchial Thermoplasty With the Alair® System in Patients With Severe Asthma|
|Study Start Date:||December 2006|
Alair Treated subject6s from PREDECESSOR STUDY
Device: Bronchial thermopladsty with the Alair System
Treatment of airways with the Alair System in PREDECESSOR STUDY
This will be a multicenter study conducted only at the clinical sites that participated in the PREDECESSOR STUDY.
Enrollment will be limited to only those subjects who were treated with the Alair System in the PREDECESSOR STUDY.
Written, informed consent will be obtained from all subjects prior to performing any study procedures.
The present study will extend the follow-up evaluation of Alair-Treated Subjects from the PREDECESSOR STUDY to 5 years post-treatment with the Alair System. These evaluations will consist of four study visits corresponding to the two-year, three-year, four-year and five-year time points following completion of Alair treatments in the PREDECESSOR STUDY. For consistency with the PREDECESSOR STUDY, ideally the subject's drug therapy should continue to be consistent with GINA Guidelines for the severity of the subject's asthma. Any changes in maintenance levels of asthma medications will be documented.
The goal of this follow-on study is to enroll all Alair-Treated Subjects who completed the PREDECESSOR STUDY. Inclusion of subjects from the treatment arm will allow for better assessment of the long-term safety of the Alair procedure.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00401986
|Irmandade Santa Casa de Misericordia de Porto Alegre|
|Porto Alegre, RS, Brazil, 90570-080|
|St. Joseph's Healthcare|
|Hamilton, Ontario, Canada, L8N 4A6|
|Hospital Laval, University of Laval|
|Sainte-Foy, Quebec, Canada, G1V 4G5|
|Gartnavel General Hospital, Univ. Glasgow|
|Glasgow, United Kingdom|
|Glenfield General Hospital, Univ. Leicester|
|Leicester, United Kingdom, LE3 9QP|
|National Heart and Lung Institute, Imperial College|
|London, United Kingdom, SW3 6NP|
|Northwest Lung Research Center, University of Manchester|
|Manchester, United Kingdom, M23 9LT|
|William Leech Center, Freeman Hospital|
|Newcastle-upon-Tyne, United Kingdom, NE7 7DN|
|Study Director:||Narinder S Shargill, PhD||Asthmatx, Inc.|